Form 4: Inari Medical CFO Mitch Hill Executes Stock Option and Sells Shares Under 10b5-1 Plan

Inari Medical's CFO, Mitch Hill, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On April 12, 2024, Mitch C. Hill, the Chief Financial Officer of Inari Medical, Inc., exercised stock options to acquire 6,000 shares of common stock at a price of $0.457 per share.
• Simultaneously, Hill sold 6,000 shares of Inari Medical common stock at a weighted average price of $40.96 per share, with individual trades ranging from $40.54 to $41.53.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by Hill on November 9, 2023.
• Following these transactions, Hill directly owns 181,294 shares of Inari Medical common stock and indirectly owns 1,600 shares through his spouse.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the CFO's outlook on the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is generally viewed as a transparent and compliant way for insiders to manage their stock holdings.

Negatives

• The sale of shares by the CFO could be interpreted negatively by some investors, although it is part of a pre-planned strategy.

Risks

• While the 10b5-1 plan provides a framework, significant insider selling could still create short-term price volatility.

Future Outlook

The document does not contain specific forward-looking statements, but the CFO's trading activity will likely continue under the 10b5-1 plan.

Industry Context

Insider transactions are common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of illegal insider trading. Investors often monitor these transactions for insights into management's perspective on the company's value.

Comparison to Industry Standards

• Comparing Inari Medical's insider trading activity to companies like Penumbra, Inc. (PEN) or Boston Scientific Corporation (BSX) shows similar patterns of executives using 10b5-1 plans for stock transactions.
• The volume and frequency of these transactions are typical for executives managing their personal finances while complying with securities regulations.
• The execution of stock options and subsequent sale of shares is a common practice among executives in the medical device industry.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations.
• Employees may perceive the transactions as a routine part of executive compensation.

Key Dates